PT4054582T - Combinações terapêuticas de acalabrutinib e capivasertib para tratar malignidades de células b - Google Patents

Combinações terapêuticas de acalabrutinib e capivasertib para tratar malignidades de células b

Info

Publication number
PT4054582T
PT4054582T PT208006171T PT20800617T PT4054582T PT 4054582 T PT4054582 T PT 4054582T PT 208006171 T PT208006171 T PT 208006171T PT 20800617 T PT20800617 T PT 20800617T PT 4054582 T PT4054582 T PT 4054582T
Authority
PT
Portugal
Prior art keywords
capivasertib
acalabrutinib
treat
cell malignancies
therapeutic combinations
Prior art date
Application number
PT208006171T
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT4054582T publication Critical patent/PT4054582T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT208006171T 2019-11-04 2020-10-30 Combinações terapêuticas de acalabrutinib e capivasertib para tratar malignidades de células b PT4054582T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962930208P 2019-11-04 2019-11-04

Publications (1)

Publication Number Publication Date
PT4054582T true PT4054582T (pt) 2025-12-10

Family

ID=73043259

Family Applications (1)

Application Number Title Priority Date Filing Date
PT208006171T PT4054582T (pt) 2019-11-04 2020-10-30 Combinações terapêuticas de acalabrutinib e capivasertib para tratar malignidades de células b

Country Status (14)

Country Link
US (1) US12691113B2 (pt)
EP (1) EP4054582B1 (pt)
JP (1) JP7575454B2 (pt)
KR (1) KR102984130B1 (pt)
CN (1) CN114728003B (pt)
AU (1) AU2020381240C1 (pt)
CA (1) CA3158321A1 (pt)
DK (1) DK4054582T3 (pt)
ES (1) ES3055126T3 (pt)
FI (1) FI4054582T3 (pt)
MX (1) MX2022005250A (pt)
PL (1) PL4054582T3 (pt)
PT (1) PT4054582T (pt)
WO (1) WO2021089419A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230286A2 (en) * 2022-05-25 2023-11-30 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
WO2024104561A1 (en) * 2022-11-15 2024-05-23 Astrazeneca Ab Therapeutic combinations of capivasertib and venetoclax

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0818533B8 (pt) 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
CN103889987B (zh) 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
AU2014360537B2 (en) * 2013-12-04 2017-09-07 Gilead Sciences, Inc. Methods for treating cancers
EP3076974A1 (en) * 2013-12-05 2016-10-12 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
JP6785804B2 (ja) * 2015-06-23 2020-11-18 ギリアド サイエンシズ, インコーポレイテッド B細胞悪性腫瘍を治療するための組合せ療法
US20170071962A1 (en) 2015-09-11 2017-03-16 Acerta Pharma B.V. Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
BR112017002594A2 (pt) * 2015-12-17 2017-12-19 Gilead Sciences Inc compostos inibidores de cinase de ligação de tank
CN107344940B (zh) * 2016-05-06 2020-04-21 广东东阳光药业有限公司 Btk抑制剂及其用途
WO2018097977A1 (en) * 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
AU2018335617B2 (en) * 2017-09-25 2021-12-09 Astrazeneca Ab Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer
TW202014184A (zh) * 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合
KR20250119664A (ko) 2018-08-29 2025-08-07 아세르타 파마. 비.브이. 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정

Also Published As

Publication number Publication date
JP7575454B2 (ja) 2024-10-29
JP2023501317A (ja) 2023-01-18
PL4054582T3 (pl) 2026-02-16
EP4054582B1 (en) 2025-09-03
FI4054582T3 (fi) 2025-12-04
CA3158321A1 (en) 2021-05-14
KR20220098175A (ko) 2022-07-11
EP4054582A1 (en) 2022-09-14
DK4054582T3 (da) 2025-12-01
AU2020381240C1 (en) 2024-02-15
WO2021089419A1 (en) 2021-05-14
AU2020381240A1 (en) 2022-06-23
US20220401442A1 (en) 2022-12-22
KR102984130B1 (ko) 2026-07-01
CN114728003A (zh) 2022-07-08
US12691113B2 (en) 2026-07-28
AU2020381240B2 (en) 2023-09-07
MX2022005250A (es) 2022-06-08
ES3055126T3 (en) 2026-02-10
CN114728003B (zh) 2025-01-28

Similar Documents

Publication Publication Date Title
IL268138A (en) Combinations of cabozantinib and atezolizumab for cancer treatment
IL292810A (en) Therapeutic compounds and methods of use
IL291018A (en) il-2 pairings and methods for their use in the treatment of autoimmune diseases
IL275517A (en) Combined methods and treatment of cancer
PL3242947T3 (pl) Terapia genowa i elektroporacja do leczenia zmian złośliwych
IL254842A0 (en) Therapeutic preparations and methods for use in cancer treatment
SG11202103588WA (en) Use of reboxetine to treat narcolepsy
HUE045916T2 (hu) Dbait molekula és PARP inhibitorok kombinációjának alkalmazása rák kezelésében
IL320805B1 (en) Therapeutic uses of tirzepatide
GB2596661B (en) Therapeutic and prophylactic use of microorganisms
IL285458A (en) Combined therapy for the treatment of b-cell malignancies
EP3268085A4 (en) Ltb4 inhibition to prevent and treat human lymphedema
IL280726A (en) Treatment of B-cell malignancies
IL279591A (en) Cancer treatment methods using combination therapy
SG11202108810YA (en) Use of vibegron to treat overactive bladder
EP3976085A4 (en) USING PRG4 TO TREAT CANCER
IL275913A (en) Methods and combined treatment for cancer treatment
EP3908370A4 (en) USE OF PHOTOBIOMODULATION THERAPY TO TREAT INFLAMMATORY AND/OR METABOLIC DISORDERS
IL267044A (en) Photodynamic therapeutic compounds and photodynamic treatment methods
HK40080179A (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
SMT202100525T1 (it) Trattamento topico per la prevenzione e la mitigazione della citotossicita' cutanea dovuta a farmaci inibitori delle tirosin-chinasi
IL270306A (en) Prevention and treatment of pre-myeloid and myeloid malignancies
IL268111A (en) Methods of treating pain
GB201812861D0 (en) Methods of administering therapy
HK40063884A (en) Combination therapy for treatment of b-cell malignancies